Mexico enlists Moderna to boost mRNA supply for respiratory diseases
The Mexican Government has struck a long-term agreement with Moderna that will see the drugmaker help the country boost its…
11 Feb 2026
FDA declines to review Moderna’s seasonal flu mRNA vaccine
The US Food and Drug Administration (FDA) has refused to review Moderna’s seasonal influenza jab, mRNA-1010, as the shifting vaccine landscape within the country continues to prove volatile for pharma…
11 Feb 2026
Gilead expects 6% of HIV sales growth in 2026, with $800m Yeztugo target
Gilead said it expects sales for its HIV portfolio to increase 6% in 2026 compared to 2025, spearheaded by growth in its recently launched pre-exposure prophylaxis (PrEP) Yeztugo (lenacapavir). Gilead’s…
11 Feb 2026
THX Pharma and Biocodex sign licensing deal for Batten-1 and TX01 drugs
THX Pharma (Theranexus) and Biocodex have entered a strategic licensing agreement to further the development of two drug candidates, Batten-1 and TX01, targeted at the Batten, Gaucher, and Niemann-Pick type…
11 Feb 2026
Insilico and CMS launch drug discovery collaborations for CNS diseases
Insilico Medicine has announced several AI drug discovery collaborations with China Medical System (CMS) across several projects in central nervous system (CNS) and autoimmune diseases. The companies plan to jointly…
10 Feb 2026
AstraZeneca bets on continued oncology demand for 2026 growth
AstraZeneca expects profits to increase in 2026, as it counts on strong demand for its oncology portfolio continuing despite geopolitical pressures and patent expiry headwinds. AstraZeneca reported full year 2025…
10 Feb 2026
REGENXBIO receives FDA response for RGX-121 application
REGENXBIO has received a complete response letter (CRL) from the US Food and Drug Administration (FDA) related to its biologics licence application (BLA) for RGX-121 (clemidsogene lanparvovec) to treat mucopolysaccharidosis II…